Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
search
Subscribe
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
Subscribe
FREE
Hepatology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Immune Dysfunction in Liver Cirrhosis Progression
October 2025
This investigation examined 72 patients with hepatitis virus infection or alcohol-related liver disease across various stages, providing a detailed picture of immune changes in cirrhosis.
Read more
8 Oct 2025
Immune Dysfunction in Liver Cirrhosis Progression
This investigation examined 72 patients with hepatitis virus infection or alcohol-related liver disease across various stages, providing a detailed picture of immune changes in cirrhosis.
6 Oct 2025
MASLD Outcomes Improved with Tirzepatide and Semaglutide
For individuals with MASLD and Type 2 diabetes, these findings suggest that tirzepatide and semaglutide could play a significant role in reducing liver-related complications
4 Oct 2025
Simple Blood Test Predicts Hepatocellular Carcinoma Survival
Crucially, these trends were observed for overall survival as well and were successfully reproduced in the separate validation set.
2 Oct 2025
Viral Hepatitis Screening and Universal Detection Strategies
Traditionally, most European and Spanish guidelines recommend viral hepatitis screening only in individuals with recognised risk factors or elevated liver enzyme levels.
30 Sep 2025
Hepatitis C Virus Eradication in Advanced Hepatocellular Carcinoma
Discover a study showing how HCV eradication with antivirals during immunotherapy improves survival, liver function, and treatment outcomes in advanced hepatocellular carcinoma.
28 Sep 2025
Low-Molecular-Weight Fucoidan in Hepatocellular Carcinoma
Recent research has investigated whether low-molecular-weight fucoidan, a compound derived from brown seaweed, could enhance the efficacy of TACE.
26 Sep 2025
High-Fibre Diet Shows Promise for Managing MASLD
A new randomised controlled trial has investigated the impact of dietary fibre supplementation on patients with T2DM and MASLD.
24 Sep 2025
Resistance Training Improves Health Outcomes in Liver Cirrhosis
Discover a study showing how resistance training can improve inflammation, oxidative stress, and physical performance in patients with liver cirrhosis.
Loading posts...
1
2
3
…
36
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View